 | | Vol. 12.16 – 30 April, 2021 |
| |
|
|
| Investigators showed that the prostate-specific homeoprotein, NKX3.1, suppressed prostate cancer initiation by protecting mitochondria from oxidative stress.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists used diagnostic leukapheresis to enrich circulating tumor cells from patients with metastatic prostate cancer and explored whether organoids provide a platform for ex vivo treatment modeling.
[European Journal of Cancer] |
|
|
|
| The authors describe an unreported function of osteoblasts as a source of testosterone that was especially relevant during androgen‐responsive metastatic prostate cancer invasion into bone.
[Journal of Bone and Mineral Research] |
|
|
|
| Scientists uncovered leptin as a novel universal target in prostate cancer (PCa) and highlighted increased intratumoral leptin and leptin receptor expression in PCa cells and patients’ tumors exposed to androgen deprivation observed in patients’ tumors of metastatic and castrate-resistant PCa.
[Endocrine-Related Cancer] |
|
|
|
| Glypican-1 induced an activated fibroblast phenotype when HS-5 cells were exposed to prostate cancer cell conditioned media.
[Scientific Reports] |
|
|
|
| Researchers identified a high-affinity BODIPY peptidomimetic targeting the prostate-specific membrane antigen (PSMA) as a potential bimodal imaging probe for prostate cancer.
[ChemMedChem] |
|
|
|
| Toluidine blue ortho-mediated photodynamic therapy was assessed on PC-3 cancer cells with various photosensitizer concentrations and light energy densities of the 655-nm diode laser.
[Photodiagnosis and Photodynamic Therapy] |
|
|
|
|
| The authors discuss and summarize the important roles of anti-programmed death-ligand 1/programmed cell death ligand-1 (PD-1/PD-L1) immunotherapy and its combination with other drugs, including chemotherapy and vaccines, in the treatment of prostate cancer.
[Molecular Therapy] |
|
|
|
|
| ESSA Pharma, Inc. announced that the company has entered into a clinical trial collaboration and supply agreement with Bayer to evaluate ESSA’s lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Bayer’s androgen receptor inhibitor, darolutamide, in patients with metastatic castration-resistant prostate cancer.
[ESSA Pharma, Inc.] |
|
|
|
| City of Hope announced that it is now recruiting patients for a Phase II clinical trial to investigate whether pills containing white button mushroom extract could regulate the immune system, affecting prostate-specific antigen levels to either remain stable or decline.
[City of Hope] |
|
|
|
|
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Cancer Research UK Beatson Institute – Glasgow, Scotland, United Kingdom |
|
|
|
| | Cyprus Cancer Research Institute – Nicosia, Cyprus |
|
|
|
| | Memorial Sloan Kettering – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
